Cargando…

Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin

Anthracyclines are anti-neoplastic drugs presenting cardiotoxicity as a side effect. Cardiac troponins (cTn) and echocardiography are currently used to assess cardiac damage and dysfunction, but early biomarkers identifying patients in need of preventive treatments remain a partially met need. Circu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gioffré, Sonia, Chiesa, Mattia, Cardinale, Daniela Maria, Ricci, Veronica, Vavassori, Chiara, Cipolla, Carlo Maria, Masson, Serge, Sandri, Maria Teresa, Salvatici, Michela, Ciceri, Fabio, Latini, Roberto, Staszewsky, Lidia Irene, Pompilio, Giulio, Colombo, Gualtiero I., D’Alessandra, Yuri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290665/
https://www.ncbi.nlm.nih.gov/pubmed/32403263
http://dx.doi.org/10.3390/jcm9051418
_version_ 1783545730877620224
author Gioffré, Sonia
Chiesa, Mattia
Cardinale, Daniela Maria
Ricci, Veronica
Vavassori, Chiara
Cipolla, Carlo Maria
Masson, Serge
Sandri, Maria Teresa
Salvatici, Michela
Ciceri, Fabio
Latini, Roberto
Staszewsky, Lidia Irene
Pompilio, Giulio
Colombo, Gualtiero I.
D’Alessandra, Yuri
author_facet Gioffré, Sonia
Chiesa, Mattia
Cardinale, Daniela Maria
Ricci, Veronica
Vavassori, Chiara
Cipolla, Carlo Maria
Masson, Serge
Sandri, Maria Teresa
Salvatici, Michela
Ciceri, Fabio
Latini, Roberto
Staszewsky, Lidia Irene
Pompilio, Giulio
Colombo, Gualtiero I.
D’Alessandra, Yuri
author_sort Gioffré, Sonia
collection PubMed
description Anthracyclines are anti-neoplastic drugs presenting cardiotoxicity as a side effect. Cardiac troponins (cTn) and echocardiography are currently used to assess cardiac damage and dysfunction, but early biomarkers identifying patients in need of preventive treatments remain a partially met need. Circulating microRNAs (miRNAs) represent good candidates, so we investigated their possible roles as predictors of troponin elevation upon anthracycline treatment. Eighty-eight female breast cancer patients administered with doxorubicin (DOX) or epirubicin (EPI) were divided into four groups basing on drug type and cTn positive (cTn+) or negative (cTn−) levels: DOX cTn−, DOX cTn+, EPI cTn− and EPI cTn+. Blood was collected at baseline, during treatment, and at follow-up. We identified plasma miRNAs of interest by OpenArray screening and single assay validation. Our results showed miR-122-5p, miR-499a-5p and miR-885-5p dysregulation in DOX patients at T0, identifying a signature separating, with good accuracy, DOX cTn− from DOX cTn+. No miRNAs showed differential expression in EPI subjects. Conversely, an anthracycline-mediated modulation (regardless of cTn) was observed for miR-34a-5p, -122-5p and -885-5p. Our study indicates specific circulating miRNAs as possible prediction markers for cardiac troponin perturbation upon anthracycline treatment. Indeed, our findings hint at the possible future use of plasma miRNAs to predict the cardiac responsiveness of patients to different anticancer agents.
format Online
Article
Text
id pubmed-7290665
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72906652020-06-17 Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin Gioffré, Sonia Chiesa, Mattia Cardinale, Daniela Maria Ricci, Veronica Vavassori, Chiara Cipolla, Carlo Maria Masson, Serge Sandri, Maria Teresa Salvatici, Michela Ciceri, Fabio Latini, Roberto Staszewsky, Lidia Irene Pompilio, Giulio Colombo, Gualtiero I. D’Alessandra, Yuri J Clin Med Article Anthracyclines are anti-neoplastic drugs presenting cardiotoxicity as a side effect. Cardiac troponins (cTn) and echocardiography are currently used to assess cardiac damage and dysfunction, but early biomarkers identifying patients in need of preventive treatments remain a partially met need. Circulating microRNAs (miRNAs) represent good candidates, so we investigated their possible roles as predictors of troponin elevation upon anthracycline treatment. Eighty-eight female breast cancer patients administered with doxorubicin (DOX) or epirubicin (EPI) were divided into four groups basing on drug type and cTn positive (cTn+) or negative (cTn−) levels: DOX cTn−, DOX cTn+, EPI cTn− and EPI cTn+. Blood was collected at baseline, during treatment, and at follow-up. We identified plasma miRNAs of interest by OpenArray screening and single assay validation. Our results showed miR-122-5p, miR-499a-5p and miR-885-5p dysregulation in DOX patients at T0, identifying a signature separating, with good accuracy, DOX cTn− from DOX cTn+. No miRNAs showed differential expression in EPI subjects. Conversely, an anthracycline-mediated modulation (regardless of cTn) was observed for miR-34a-5p, -122-5p and -885-5p. Our study indicates specific circulating miRNAs as possible prediction markers for cardiac troponin perturbation upon anthracycline treatment. Indeed, our findings hint at the possible future use of plasma miRNAs to predict the cardiac responsiveness of patients to different anticancer agents. MDPI 2020-05-11 /pmc/articles/PMC7290665/ /pubmed/32403263 http://dx.doi.org/10.3390/jcm9051418 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gioffré, Sonia
Chiesa, Mattia
Cardinale, Daniela Maria
Ricci, Veronica
Vavassori, Chiara
Cipolla, Carlo Maria
Masson, Serge
Sandri, Maria Teresa
Salvatici, Michela
Ciceri, Fabio
Latini, Roberto
Staszewsky, Lidia Irene
Pompilio, Giulio
Colombo, Gualtiero I.
D’Alessandra, Yuri
Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
title Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
title_full Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
title_fullStr Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
title_full_unstemmed Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
title_short Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
title_sort circulating micrornas as potential predictors of anthracycline-induced troponin elevation in breast cancer patients: diverging effects of doxorubicin and epirubicin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290665/
https://www.ncbi.nlm.nih.gov/pubmed/32403263
http://dx.doi.org/10.3390/jcm9051418
work_keys_str_mv AT gioffresonia circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT chiesamattia circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT cardinaledanielamaria circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT ricciveronica circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT vavassorichiara circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT cipollacarlomaria circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT massonserge circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT sandrimariateresa circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT salvaticimichela circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT cicerifabio circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT latiniroberto circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT staszewskylidiairene circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT pompiliogiulio circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT colombogualtieroi circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin
AT dalessandrayuri circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin